CorWave is a medical device company developing innovative heart pumps (Left Ventricular Assist Devices, LVADs).
Their mission is to lower the burden associated with LVADs by curbing pump-related adverse events and reducing the invasiveness of the surgery. They are leveraging a unique and patented pumping technology that overcomes the drawbacks of rotary pump systems. Inspired by nature, CorWave technology can mimic the native heart blood flow pattern (low shear and pulsatile), reduces energy-requirements and gives opportunities to downsize LVADs further.
CorWave was founded in 2012 by MD Start and received funding from top-tier investors including Ysios, Sofinnova, Seventure, Medtronic, Novo and Bpifrance.
- Invested amount
EUR 14 999 995.92
- Press Release
"The EIC Fund has played an instrumental role in CorWave's quest to improve the lives of advanced heart failure patients."
Louis de Lillers, CEO